3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
18
Phase 2
8
Phase 3
2
Phase 2/3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
1
Interventions
Cisplatin
29
Carboplatin
28
Gemcitabine
27
Paclitaxel
26
pembrolizumab
24
Capecitabine
16
Pemetrexed
15
Bevacizumab
15
Docetaxel
14
Oxaliplatin
13
Fluorouracil
12
Drug Therapy
12
Nivolumab
10
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
anlotinib
7
Injections
7
Rituximab
6
venetoclax
5
atezolizumab
5
Temozolomide
5
Leucovorin
5
Ipilimumab
5
Lenalidomide
4
Irinotecan
4
Interferon alpha-2
4
Folfox protocol
4
Dexamethasone
4
Azacitidine
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
INDUSTRY
×
cediranib
×
Clear all
NCT00384176
2017-04-14
HORIZON III
AstraZeneca
Phase 2/3
Completed
1,814 enrolled
13 charts